Nick Cerrito is the Global Head of the firm’s Life Sciences Practice. His practice focuses on Hatch-Waxman litigation and client counseling in the pharmaceutical industry, with an emphasis on creating strategies at the interface of patent and FDA laws. He has represented large innovator pharmaceutical companies, established biotechnology companies, and start-ups. Mr. Cerrito’s practice also includes, IPR’s/CBM’s, transactional work and due diligence in the areas of pharmaceutical product acquisition, strategic planning, and patent prosecution strategies.
Mr. Cerrito has represented and continues to represent the patentees for Revlimid, a product approved for the treatment of Multiple Myeloma, which has annual revenues in excess of $8 billion dollars. He is also lead counsel for the patentee in Hatch-Waxman cases relating to Abraxane®, Xyrem®, and Pomalyst® among others. Nick’s past representations have also included Namenda®, Altace®, Avinza® Oxycontin®, Moexipril®, Skelaxin®, Cardizem®, Sonata®, Itsodax®, Qysima® and Thalomid®. As co-lead trial counsel, he successfully represented the only defendant to prevail in the first-wave Prilosec® litigation, at that time the largest pharmaceutical litigation ever.